Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205343 · ClinicalTrials.gov registry record
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
A clinical trial of GastroEsophageal Cancer and Gastrostomy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 20
- Enrollment target
- 4
- Study locations
NCT05205343: Recruiting study of GastroEsophageal Cancer and Gastrostomy, sponsored by M.D. Anderson Cancer Center.
NCT05205343 is a study of GastroEsophageal Cancer and Gastrostomy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05205343, a study of GastroEsophageal Cancer and Gastrostomy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Primary Outcome
Appetite level (reported on a 0-10 scale, in Q8 of MDASI-GI) scale 0-not present-10 as bad as you can image
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER Control Group
Study Locations (4)
Other
- Keio University School of Medicine - Tokyo
- Yonsei University College of Medicine - Soeul
Minnesota
- Mayo Clinic in Rochester - Rochester
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-05-31 |
What NCT05205343 shows while recruiting
NCT05205343 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT05205343 reports a single indexed study location in Other, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT05205343 about?
NCT05205343 is a clinical study titled "Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers". To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
What is the current status of trial NCT05205343?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-05-11. Estimated completion is 2026-05-31.
What conditions does trial NCT05205343 study?
This clinical trial studies the following conditions: GastroEsophageal Cancer, Gastrostomy, Gastric.
What interventions are being tested in trial NCT05205343?
The interventions under investigation include: Standard of Care (OTHER), Control Group (OTHER).
Who is sponsoring clinical trial NCT05205343?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05205343 being conducted?
This trial has 4 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GastroEsophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05205343's enrollment target sits among peer trials
20 22nd of 23 higher than 2 of 23 other GastroEsophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other GastroEsophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
RECRUITING · NA
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
RECRUITING · Phase 2
-
Sample Collection for Ongoing Research and Product Evaluation Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI